
Co-Diagnostics (CODX) Stock Forecast & Price Target
Co-Diagnostics (CODX) Analyst Ratings
Bulls say
Co-Diagnostics Inc is experiencing growth prospects in the respiratory infectious disease diagnostics market, particularly influenced by significant investments in Saudi Arabia, which is expected to enhance its operational reach. The company's strategic partnership with Arabian Eagle Manufacturing through the joint venture CoMira Diagnostics will facilitate the development, distribution, and commercialization of its innovative Co-Dx technologies across 18 MENA nations. Additionally, Co-Diagnostics is advancing its proprietary sample preparation instrument aimed at reducing costs for PCR testing, while also pursuing regulatory approvals for enhancements to its COVID-19 testing, underscoring its commitment to expanding access to affordable diagnostics.
Bears say
Co-Diagnostics, Inc. faces significant risks that negatively impact its financial outlook, including potential failures in clinical evaluations and the inability to secure necessary regulatory clearances, which could hinder commercial success amid a competitive landscape. The company reported a modest revenue of $145,000 for the third quarter of 2025 while incurring a substantial net loss of $5.9 million, translating to a loss of $0.16 per share. Additionally, concerns regarding the dilution risk associated with future fundraising efforts, which may come with less favorable terms, further exacerbate the bleak financial perspective for the company.
This aggregate rating is based on analysts' research of Co-Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Co-Diagnostics (CODX) Analyst Forecast & Price Prediction
Start investing in Co-Diagnostics (CODX)
Order type
Buy in
Order amount
Est. shares
0 shares